Health & Fitness
Health and Fitness
Health and Fitness
Thu, January 29, 2009 Bio-Imaging Technologies to Present at the UBS Global Healthcare Services Conference on February 9, 2009 at the Waldorf Astoria
NEWTOWN, Pa.--([ BUSINESS WIRE ])--Bio-Imaging Technologies, Inc. ("Bio-Imaging") (NASDAQ: BITI) today announced Mark L. Weinstein, President and Chief Executive Officer will be presenting at the UBS Global Healthcare Services Conference in New York City on Monday, February 9, 2009 at 2 p.m.
Mr. Weinstein will be discussing an overview of Bio-Imaging Technologies, including its focus on providing clinical trial services, including medical image management and eClinical data services to support the product development process for the pharmaceutical, biotechnology and medical device companies.
The UBS Global Healthcare Services Conference is being held February 9 – 11, 2009 at the Waldorf Astoria Hotel in New York City.
Bio-Imaging Technologies, Inc. is a healthcare contract service organization providing services that support the product development process of the pharmaceutical, biotechnology and medical device industries. The Company has specialized in assisting its clients in the design and management of the medical-imaging component of clinical trials since 1990. Bio-Imaging serves its clients on a global basis through its Core Labs in Newtown, PA, and Leiden, The Netherlands, along with business offices in the United States, The Netherlands, Germany and France. Phoenix Data Systems, Inc., a division of Bio-Imaging Technologies, is a leading global clinical data services provider of electronic data capture (EDC) services and a comprehensive array of broadly interoperable eClinical data solutions to the pharmaceutical and biotechnology industries. Phoenix Data Systems delivers full service EDC, a unique combination of electronic data capture, interactive voice response, reporting, and data management solutions. Additional information about Bio-Imaging is available at [ www.bioimaging.com ].
Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995.In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements.The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control.The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements.The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent form 10-Q.
